Browse Articles
Discover research articles across all indexed journals
Substrate and inhibitor specificity of Plasmodium nucleoside transporters ENT1 orthologs
Outcomes of patients with peritoneal-limited metastatic gastric cancer (PLGC) undergoing bidirectional (BD) chemotherapy cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC).
328 Background: The prognosis of PLGC patients (pts) is poor with standard systemic therapy. PLGC pts who undergo CRS after BD chemotherapy (chemo) demonstrate prolonged survival. We retrospectively analysed the outcomes of pts who underwent BD chemo followed by CRS and HIPEC in a single institution, stratifying by peritoneal carcinomatosis index (PCI) and chemo regimen. Methods: PLGC pts who received BD chemo between January 2016 to September 2023 were enrolled and consented for data collection. BD chemo was either 3 weekly paclitaxel (PTX) (50mg/m2), S-1 (80mg/m2) and IP PTX (20mg/m2) or capecitabine (2g/m2), oxaliplatin (100mg/m2) (CAPOX) and IP PTX (40mg/m2). HIPEC utilised cisplatin 50mg/m2 at 40 for 60 minutes. Trastuzumab and nivolumab were given selectively. Pts without radiological progression after 24 weeks of BD chemo, with PCI7 and potential for complete resection underwent CRS including D2 gastrectomy and HIPEC. Post-resection, BD chemo was stopped. Survival was analysed by Kaplan Meier curves, adverse events (AEs) by CTCAE v5.0 and response by independent radiological review. Results: 34 pts were enrolled with median follow-up of 26.9 months (m). Median (range) age was 51 (17 – 79) and median PCI 12 (0-29). 52.9% were female, 8.8% had Cy1 only disease and 38% had prior gastrectomy. 3 out of 6 pts with evaluable disease had partial response. Median progression-free survival and overall survival (mOS) was 9.1m and 16.5m respectively. 7 pts (20.6%) underwent CRS with median (range) PCI of 1 (0-15.0). mOS in CRS vs non-CRS pts was 23.8m vs 14.6m (p=0.4); PCI <7 vs PCI ≥7 was 23.8m vs 14.6m (p=0.63); and CAPOX vs S1/PTX systemic chemotherapy was 23.9m vs 14.6m (p=0.29) respectively. Peritoneal cytology negativity increased from 25.8% to 86.4% after BD chemo. Peritoneal lesions biopsied post-BD chemo showed no tumour cells in 64% of cases. There was no treatment-related mortality. 1 pt had IP port removal due to complications. The commonest grade 3 AE was neutropenia (14.7%). Biomarker analysis is currently being performed. Conclusions: BD chemo CRS HIPEC was well tolerated with longer survival in patients undergoing CRS. Evaluation of tumour using PCI post-BD chemo may be sub-optimal.
Treatment preferences in advanced pancreatic ductal adenocarcinoma (PDAC) from qualitative patient (PT), caregiver (CG), and oncologist (OC) interviews.
712 Background: Most treatment regimens for patients with PDAC focus on extending survival while managing symptoms and maintaining quality of life (QoL). Here we report insights from PT, CG, and OC interviews on PDAC treatment preferences. Methods: A targeted literature review of 7 quantitative/preference and 12 qualitative/patient-reported outcome studies was used to develop semi-structured interview guides. Single 60-minute interviews of US PTs with stage 4 PDAC, CGs, and OCs with ≥5 years’ experience treating PDAC were undertaken virtually by staff from March to April 2024. Interviews had 5 sections: background/clinical experience (OC only); key treatment benefits and risks to avoid (ranked by importance); treatment convenience; and 2 hypothetical treatment preference questions. Participants completed a sociodemographic and clinical questionnaire. Interviews were recorded with permission, transcribed, and analyzed with ATLAS.ti v8+. Results: Ten PTs, CGs, and OCs completed interviews (N=30 total), including 4 PT/CG dyads. Mean PT age was 56.8 (standard deviation [SD] 12.15) years; 6 were men and 4 did not have CGs. Mean CG age was 51.1 (SD 14.2) years; 9 were women and 7 cared for their partners. OCs had mean 18.5 (SD 6.9) years’ clinical experience and 10 were men. Top-ranked treatment benefits were increased overall survival (OS) (6 PTs [60%], 8 CGs [80%], 7 OCs [70%]); improved QoL (6 PTs [60%], 5 CGs [50%], 7 OCs [70%]); stopping disease progression (5 PTs [50%], 3 CGs [30%], 7 OCs [70%]), and increased life expectancy (7 PTs [70%], 5 CGs [50%], 3 OCs [30%]). PTs’ top 3-ranked side effects to avoid included fatigue (n=4 [40%]), nausea (n=4 [40%]), and vomiting (n=3 [30%]). CGs ranked trouble remembering (n=4 [40%]), neutropenia (n=4 [40%]), and neuropathy (n=3 [30%]) in the top 3, while OCs ranked vomiting (n=5 [50%]), neuropathy [n=5 [50%]), and neutropenia (n=4 [40%]) highest. Most PTs/CGs were indifferent to ≥1 infusion/visit and infusion duration. In the first hypothetical treatment preference question, the treatment with higher efficacy but higher side effect risk and longer infusion time was preferred by 80% of PTs/CGs and 70% of OCs. In the second hypothetical treatment question, treatments had the same efficacy; 90% of PTs/CGs/OCs preferred the treatment with shorter infusion time and lower risk of gastrointestinal side effects and hypersensitivity reactions, despite higher risk of severe hypokalemia and severe neutropenia. Conclusions: OS and QoL were ranked as similarly important by participants, suggesting that extending survival is insufficient without acceptable QoL. Avoiding side effects was important to all participants, though PTs, CGs, and OCs ranked specific risks with differing importance. More studies are needed to quantify tradeoffs between treatment efficacy and side effects in the care of patients with advanced PDAC.
CK2 expression gastrointestinal cancer: Exploring clinical characteristics and cancer genetics.
834 Background: The expression of protein kinase CK2 subunits (CSNK2A1, CSNK2A2, CSNK2A3, and CSNK2B) in gastrointestinal cancers has not been fully characterized. In this study, we seek to evaluate how changes in CK2 subunit expression are associated with GI cancer clinical characteristics and genetics. Methods: Data analysis was performed with data from The Cancer Genome Atlas (TCGA). R version 4.2.2 was used for analysis. We provide an analysis of several cancer cohorts looking at CK2 subunit expression, as well as cancer mutations, copy number alterations, and clinical characteristics. Results: From the TCGA datasets containing mRNA expression data, we assessed hepatocellular carcinoma (n=361), colorectal adenocarcinoma (n=339), gastric adenocarcinoma (n=306) and diffuse type gastric adenocarcinoma (n=69), pancreatic adenocarcinoma (n=169), esophageal adenocarcinoma (n=89) and squamous cell carcinoma (n=95), and cholangiocarcinoma (n=36). We explored associations between CK2 subunit expression and GI cancer-specific known driver mutations, of which we report the following significant findings (p < 0.05 for all). Mutations in TP53 were associated with increased expression of CSNK2A1 in hepatocellular carcinoma and stomach adenocarcinoma, increased CSNK2A2 in colorectal adenocarcinoma, and CSNK2B in colorectal adenocarcinoma, pancreatic adenocarcinoma, and stomach adenocarcinoma. Mutations in KRAS were associated with increased expression of CSNK2A1 and CSNK2B in pancreatic adenocarcinoma. Mutations in BRAF were associated with decreased expression of CSNK2A2 and CSNK2B in colorectal adenocarcinoma. We also noted significant changes in CSNK2 subunit expression when looking at mutations and copy number alterations in signaling pathways such as Wnt, NOTCH, PI3K, TGFβ, and more. We also explored associations between CK2 subunit expression and GI cancer clinical characteristics, of which we report the following significant findings (p < 0.05 for all). In colorectal adenocarcinoma, increased CSNK2A2 expression was associated with lymph node invasion and advanced clinical stage. In hepatocellular carcinoma, increased CSNK2A1 and CSNK2A3 expression was associated with greater tumor grade, tumor size, and more advanced clinical staging. Increased CSNK2A2 expression was associated with greater tumor size, more advanced clinical staging, and vascular invasion. Increased CS2NKB expression was associated with increased tumor grade, size, and vascular invasion. In pancreatic adenocarcinoma, increased CSNK2A3 expression was associated with a worse response to the first treatment course. Conclusions: Our results suggest that changes in protein kinase CK2 expression are associated with different cancer clinical characteristics as well as cancer-specific mutations and signaling pathways.
Beamion BCGC-1: A phase Ib/II trial of the HER2-selective tyrosine kinase inhibitor (TKI) zongertinib (BI 1810631) + trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) for patients with metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC).
TPS509 Background: Approximately 15% of mGEAC tumors overexpress HER2. Currently, the HER2-targeted antibody-drug conjugate (ADC), T-DXd, is approved in mGEAC as a second-line or later-line treatment option following the failure of prior trastuzumab-containing therapy. Zongertinib (BI 1810631) is a novel, orally administered HER2-selective TKI that spares EGFR. In a Phase I trial (NCT04886804), zongertinib showed encouraging tolerability and efficacy in patients with HER2 aberration-positive advanced solid tumors, including mGEAC. Beamion BCGC-1 (NCT06324357) is a Phase Ib/II dose escalation/optimization trial investigating zongertinib plus T-DXd or T-DM1 in patients with HER2+ mGEAC or mBC. Here we focus on the mGEAC cohorts, in which patients will receive zongertinib in combination with T-DXd. Methods: Across the whole trial, approximately 240 patients will be enrolled from approximately 48 sites in 6 countries. In the mGEAC cohorts, approximately 80 patients with histologically/cytologically confirmed locally advanced/metastatic, unresectable, HER2-positive, pre-treated mGEAC will be enrolled. All patients must have investigator-assessed progression and documented HER2-positive disease (overexpressed and/or amplified; confirmed by immunohistochemistry and in situ hybridization). In Phase Ib, approximately 20 patients will receive escalating doses of zongertinib plus a fixed approved dose of T-DXd (6.4 mg/kg, once every 21 days). Dose escalation will be guided by a Bayesian Logistic Regression Model, with overdose control. In Phase Ib, the primary endpoint is the occurrence of dose-limiting toxicities (DLTs) during the maximum tolerated dose evaluation period (first 21-day cycle); secondary endpoints include objective response (RECIST v1.1), DLTs during the on-treatment period and pharmacokinetics. In Phase II, up to 60 patients with mGEAC will be randomized 1:1 to receive one of two zongertinib dose levels (dose levels informed by Phase Ib), plus a fixed approved dose of T-DXd. In Phase II, the primary endpoint is objective response; secondary endpoints include progression-free survival, disease control, treatment-emergent adverse events leading to dose reduction, pharmacokinetics and patient-reported outcomes. Patients will remain on treatment until disease progression, undue toxicity or any other protocol-defined stopping criterion. Enrollment is ongoing. Clinical trial information: NCT06324357 .
Assessing hazard prediction and risk calibration skills in experienced and novice e-scooter riders
Abstract Less experienced e-scooter riders often exhibit risky riding behaviours. Despite this, no studies have examined how riders calibrate risk, respond to hazardous situations, and the impact of riding experience on these skills. To address this, this study assessed hazard prediction and risk calibration in e-scooter riders via bespoke video-based tests featuring real e-scooter footage filmed from the rider’s perspective. The first experiment assessed the ability of e-scooter riders to predict hazardous riding scenarios. The second experiment evaluated their proneness to engage in risky riding situations. The results indicated that increased riding experience did not improve riders’ hazard prediction skills or reduced their proneness to engage in risky riding. In fact, a higher riding frequency was linked to an increased tendency to engage in risky behaviour in certain scenarios. The results highlight that the typically short duration of e-scooter trips may limit riders’ exposure to a variety of hazards, hindering their ability to develop effective risk calibration skills. The observed high propensity to engage in risky riding scenarios, combined with average hazard prediction scores, emphasizes the need for targeted rider training focused on vigilance and risk awareness.
SF3B1 thermostability as an assay for splicing inhibitor interactions
Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan.
490 Background: c-Met protein (MET protein) overexpression (OE) and MET amplification (amp) occur in several cancer types, including GEA, and are associated with poor prognosis. The c-Met–directed antibody-drug conjugate telisotuzumab adizutecan (ABBV-400) is being assessed in advanced solid tumors in an ongoing, first-in-human study (NCT05029882). Results showed promising antitumor activity and a tolerable safety profile in GEA (Strickler et al. ESMO 2024, 1439P). Here, we present our analysis on associations between c-Met OE, MET amp, and ctDNA-derived molecular response with clinical outcomes. Methods: c-Met expression was evaluated retrospectively in FFPE tissue (archival/fresh) collected at study screening using IHC (SP44 Ab clone) or whole transcriptomic RNA sequencing (Caris). Plasma ctDNA collected at baseline (BL) and cycle 3 day 1 (C3) was analyzed with the GuardantINFINITY assay. Molecular response (MR) was assessed using circulating tumor fraction (cTF), estimated on the basis of ctDNA variant allele frequencies in a 74-gene panel (Guardant360 CDx) and methylation signals (GuardantINFINITY methylome platform). MR was defined as a 50% decrease in cTF from BL. MET amp status was determined retrospectively by the Guardant Health algorithm. Radiographic response was assessed per RECIST v1.1. Results: Clinical data from 42 patients (pts) with advanced GEA were included in this biomarker analysis. There was a negative correlation between c-Met expression and tumor size change from BL (R=-0.59). Of 42 pts, 12 (29%) had tumors with MET amp per ctDNA analysis/local site reports, which was higher than the bioinformatic analysis of real-world data (Caris-ConcertAI linked RWD360 and PT360; ~3%). Concordance between c-Met expression per IHC and RNA was observed (R=0.75, p<10 -6 ). There were 12 responders; 7 (58%) had MET amp, and 5 (42%) did not. Responders had lower ctDNA percentage change from BL vs nonresponders (1.5-fold and 1.6-fold difference based on 74-gene and methylation panel, respectively). Pts with MR had a greater decrease in tumor size from BL vs those without MR. A positive correlation between change in ctDNA levels (BL to C3) and change in tumor size was observed using the 74-gene panel and methylation panel (R=0.73 and 0.69, respectively). Additional biomarker analyses focused on the association between MET and other key biomarkers relevant in GEA will be discussed. Conclusions: In pts with advanced GEA treated with telisotuzumab adizutecan, c-Met OE/ MET amp and ctDNA-based MR were associated with enhanced antitumor activity. Compared with real-world data, MET amp was enriched in this study population. Phase 2 studies will continue to explore c-Met OE and MET amp prevalence and their potential predictive value with other biomarkers in a clinically representative population. Clinical trial information: NCT05029882 .
Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A prospective multicenter intra-individual comparison trial.
530 Background: Hepatocellular carcinoma (HCC) often recurs following curative treatment, significantly impacting long-term survival. Contrast-enhanced multiphasic computed tomography (CECT) is widely utilized for HCC recurrence surveillance but carries risks such as radiation exposure and adverse reactions to contrast agents. This prospective multicenter trial aimed to compare the accuracy of non-contrast abbreviated magnetic resonance imaging (NC-MRI) with CECT in detecting late recurrent HCC. Methods: This prospective multicenter intra-individual head-to-head comparison trial (study identifier: NCT05690451, KCT0006395) enrolled participants who had undergone curative treatment for HCC and remained recurrence-free for over two years. Participants underwent three rounds of surveillance at 2–6-month intervals using both CECT and NC-MRI. The primary outcome was the detection accuracy of each modality, compared using the McNemar test. Secondary outcomes included detection sensitivity and specificity. Results: A total of 203 participants underwent 528 rounds of paired CECT and NC-MRI, detecting recurrent HCC in 22 participants (10.8%). Among these cases, 21 showed intrahepatic recurrent HCC with a median tumor size of 1.3 cm, and one exhibited aortocaval lymph node metastasis. NC-MRI demonstrated a detection accuracy of 96.6% (196/203), significantly higher than CECT's 91.6% (186/203) (P=0.006). NC-MRI also exhibited significantly higher sensitivity in detecting recurrent HCC compared to CECT (77.3% [17/22] vs. 36.4% [8/22]; P=0.012), while specificity did not differ significantly between NC-MRI and CECT (98.9% [179/181] vs. 98.3% [178/181]; P=0.999). Conclusions: NC-MRI showed significantly higher sensitivity and accuracy in detecting recurrent HCC among patients who had been disease-free for more than two years after curative treatment, establishing it as the preferred surveillance modality for late recurrence. Clinical trial information: NCT05690451 . Contrast enhanced CT Non-contrast MRI Difference, % (95% CI) P-value Estimates, % (n/N) 95% CI, % Estimates, % (n/N) 95% CI, % Accuracy 91.6% (186/203) 87.8-95.5 96.6% (196/203) 94.0-99.1 4.9 (1.7, 8.2) 0.006 Sensitivity 36.4% (8/22) 14.5-58.2 77.3% (17/22) 58.3-96.3 40.9 (16.8, 65.0) 0.012 Specificity 98.3% (178/181) 96.5-100 98.9% (179/181) 97.4-100 0.6 (-0.5, 1.6) 0.999
Erratum: A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease
Impact of synchronous vs metachronous primary tumor resection on prognosis of BRAF-V600E mutant metastatic colorectal cancer (mCRC).
304 Background: The goal of this study is to evaluate if resection of the primary tumor in synchronous versus metachronous metastatic disease predicts survival of BRAF-V600E mCRC in the era prior to combination BRAF/EGFR inhibitors. Methods: This is a retrospective study of patients treated at the Ottawa Hospital Cancer Centre with BRAF-V600E mutation mCRC who did not receive combination BRAF/anti-EGFR therapy, diagnosed with colorectal cancer prior to March 31, 2021. Demographic, clinical, pathologic and cancer characteristics were abstracted from electronic medical records. Outcomes of interest included median duration of therapy and overall survival (OS). Results: 71 patients were included with a median age of 70 years:, 37 (52%) were females, 49 (69%)had right-sided tumors and 19 (27%) were mismatch repair deficient (dMMR). The primary tumor was unresected in 22 (30%) and resected in 49 (70%), completely resected in 44 (62%), and partially resected in 5 (7%) patients. Overall, median OS was 12.9 months 95% CI (8.4, 19) with 17 months 95% CI (11, —) mOS in patients with resected primary and 6.3 95% CI (4.8, 15) months in patients with unresected primary, HR 2.48 95% CI (1.42, 4.32), p=0.001. In univariate analysis: signet ring cell (p=0.007), good performance status (p<0.001), distant lymph nodes (p<0.001), peritoneal metastasis (p=0.008), metasetectomy (p=0.002), Charlston Comorbidity Index (p=0.003) were significant prognostic factors. Synchronous versus metachronous primary tumour was not a significant prognostic factor. Conclusions: Real world data confirms that patients with BRAF-V600E mutant mCRC have poor clinical outcomes. Our analysis suggests that resection of the primary tumor did not seem to impact on survival of BRAF-V600E mutant mCRC patients. This suggests that prognosis is dictated by the systemic disease and not complications of the primary tumour itself. Of the patients with unresected primary tumour (n=21), 6 were synchronous. Metastatic status Primary Tumor Resected Primary Tumor unresected Total Synchronous 23 22 45 Metachronous 26 0 26 Total 49 22 71
2024 FDA approvals exceed average number but have lower sales projections
Copper and iron as unique trace elements linked to fibromyalgia risk
Dilated cardiomyopathy variant R14del increases phospholamban pentamer stability, blunting dynamic regulation of calcium
Financial toxicity in patients with newly diagnosed hepatocellular carcinoma.
538 Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths and has been associated with significant patient (pt) financial liability, however no study has yet examined pt-reported measures of financial toxicity (FT) in this population. We sought to assess pt-reported FT in newly diagnosed HCC and to identify pt-, disease-, and treatment-related factors associated with FT. Methods: Pts with HCC were recruited prior to treatment initiation during their initial visit at a multidisciplinary liver cancer clinic at a tertiary care center between January 2023-May 2024. The Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT), a validated survey for assessing financial distress in pts with cancer (range, 0-44; lower scores reflect worse financial wellness), was completed by participants during their initial visit. Sociodemographic (age, sex, race, ethnicity, primary language, insurance status, employment status, marital status, highest education completed, household income, living arrangement, home zip code), clinical (Barcelona Clinic Liver Cancer stage, performance status, age-adjusted Charlson comorbidity index, albumin-bilirubin score, presence and etiology of chronic liver disease, Child-Pugh grade, MELD-Na score), and planned treatment (surgery, liver-directed therapy, systemic therapy, clinical trial enrollment) characteristics were evaluated by questionnaires or medical record review. The EORTC QLQ-HCC18 was used to assess pt-reported quality of life (QOL). Area Deprivation Indices were calculated using pts’ home zip codes. Mean COST-FACIT scores were compared using two-sided t test for binary variables and one-way ANOVA for non-binary variables. Results: Among 47 pts enrolled, 35 (74%) completed the COST-FACIT survey. Younger age (<65 vs ≥65 yrs; mean, 20.3 vs 27.8; p=0.05), non-English primary language (non-English vs English; mean, 16.2 vs 26.7; p=0.04), less completed education (high school or earlier vs college or beyond; mean, 23.3 vs 32.0; p=0.02), and worse self-reported QOL (EORTC QLQ-HCC18 score ≥cohort median vs <cohort median; mean, 21.4 vs 29.2; p=0.02) were significantly associated with worse FT. Although not statistically significant, Hispanic ethnicity (Hispanic vs not Hispanic; mean, 16.1 vs 26.4; p=0.07), lack of employment (not employed vs retired vs employed; mean, 15.5 vs 29.4 vs 24.3; p=0.07), and no plan for liver-directed therapy (no vs yes; mean, 17.9 vs 26.7; p=0.07) trended towards worse pt-reported FT. Conclusions: Among pts with newly diagnosed HCC, significantly higher pt-reported FT is associated with younger age, non-English primary language, less completed education, and worse QOL. Efforts are underway to longitudinally follow our study cohort to assess the course of self-reported FT over 1-year follow-up as well as its associations with treatment response and survival.
Disparities in organ preservation rate for high-risk stage I rectal cancer.
37 Background: Guidelines for the treatment of high-risk stage I rectal cancer is a curative oncologic resection, while recommendations for stage II/III rectal cancer include neoadjuvant therapy with the option for organ preservation. The paradoxical nature of treating less advanced stage cancer with more morbid surgery calls into question the use of organ preservation strategies (OP) for less advanced disease. While sphincter preservation is appealing, benefits from OP require commitment to preoperative therapy, which may require more significant time and financial commitments than a single-stage curative treatment. This study aims to evaluate disparities in social determinants of health regarding receipt of OP compared to major oncologic resection for high-risk stage I rectal cancer. Methods: The National Cancer Database was queried to analyze all patients with high-risk stage 1 rectal cancer between 2004-2021. High-risk stage 1 disease was defined as either T2 or T1 tumors with lymphovascular invasion, or grade 3 or 4 differentiation. Covariates in patients who underwent OP, defined as chemoradiation therapy without oncologic resection or local excision, were compared to those who underwent major oncologic resection. Additional variables included age, sex, race, great circle distance, insurance status, education, facility type, income, rurality, and comorbidity index. Univariate and multivariate analyses were utilized to compare association of covariates to OP. Results: Of the 63,762 patients included, 9,261 (14.5%) underwent OP. Increased rates of OP were seen with increasing age (OR 1.029, p<0.0001), female sex (OR 1.147, p<0.0001), higher education level (OR 1.179, p=0.0034), rurality (OR 1.273, p=0.0003) and lower income (OR 0.757 for income >74K, p <0.0001). Interestingly, OP was more frequently utilized at community cancer centers in comparison to comprehensive cancer centers (OR 0.78, p<0.0001) and academic centers (OR 0.842, p=0.0021). Race, insurance status, distance to treatment, and comorbidity index were not statistically significant predictors of OP. Of note, those who underwent OP had a considerable delay in time to first treatment, with median time to treatment of 36 days in comparison to 13 days for oncologic resection. Conclusions: Socioeconomic and demographic variables are associated with receipt of OP. While plausible that a treatment strategy that requires frequent office visits, travel expenses, and time off from work may preclude OP, lower income and rurality had increased odds of OP. Future aims should be directed to identifying root causes of disparities in treatment and their clinical consequences.
Phase II preoperative pembrolizumab for MSI high or MSS/PD-L1 gastric cancer followed by surgery and adjuvant therapy with pembrolizumab (NCT03257163): Results of a multicenter study.
441 Background: Data suggest that patients with tumors with microsatellite instability (MSI-H), EBV expression, or positive PD-L1 expression can benefit from immunotherapy. This trial evaluated PD-1 immunotherapy in this subset of patients with operable gastric cancer. Methods: We present results of a phase 2 multi-institutional clinical trial (NCT03257163). Patients with cT2-T4, N0-N3, M0 gastric adenocarcinoma with MSI-H, PDL1 CPS > 1%, or EBV+ were included. Patients received 2 cycles preop pembrolizumab 200 mg IV q3 weeks followed by surgery. Pembrolizumab was given for 16 additional cycles postoperatively, concurrently with adjuvant chemoradiation (45 Gy) and 5 cycles of capecitabine (825 mg/m2 days 1-14 during cycles 3, 6 and 7; 625 mg/m2 BID days 1-14 during cycles 4 and 5 with radiation). Patients were defined as evaluable if they received > one cycle of postop pembrolizumab. Primary endpoint is DFS, powered to detect 3-yr DFS of 70% with 89% power. Results: All enrolled patients received two cycles of pembrolizumab preoperatively (n=45). Eight patients did not undergo surgery (1 due to frailty, 2 with distant progression on preoperative imaging, 2 with peritoneal disease on surgical exploration and 3 with locally advanced, unresectable tumors). Six patients did not receive adjuvant therapy (2 due to surgical complications, 2 for failure to thrive, 1 refusal and 1 pending adjuvant therapy). 31 patients received adjuvant therapy and are included in the predetermined, evaluable analytic cohort. These 31 patients had a median age of 67 years (range 44 – 85) with 22.6% Hispanic, 29.0% Asian, 25.8% Black and 25.8% White. Median follow-up was 31.1 months (range 3.45-63.8). In these patients, 14 (45.2%) had MSI-H, 2 (6.5%) EBV+, and 29 (93.5%) had PDL1 expression >1% tumors. Most tumors were advanced stage with 81% ≥ cT3 and 58% cN+. In the 31 evaluable patients, the 3-year DFS was 79.4%; 3-year OS was 78.9%. For MSI-H patients, 3-year DFS was 81.8%. For patients with MSS/PD-L1+ tumors, 3-year DFS was 77.8%. For the 45-patient cohort, 3-year DFS was 70%; 3-year OS was 65%. Three patients had pCR, two with MSI-H tumors and one with PD-L1 CPS of 4%. Downstaging occurred in 62.2% of patients, and 40% of surgical specimens had pT0/T1 tumors consistent with significant pathologic responses. Conclusions: A biomarker-driven preoperative treatment strategy for MSI-H, EBV+, and MSS/PDL1+ operable gastric adenocarcinoma patients is promising and warrants additional evaluation. This treatment strategy is novel and effective, and it incorporates immune checkpoint immunotherapy, low dose chemotherapy, and radiation thus avoiding more intensive combination chemotherapy regimens for patients with these biomarkers. Clinical trial information: NCT03257163 .
Assessment of pathologic response in the colorectal cancer cohort of the IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors.
241 Background: Neoadjuvant treatment with immune check point inhibitors has shown promising results in localized deficient mismatch repair/microsatellite instability (dMMR/MSI) colorectal cancer (CRC), notably in terms of pathologic response. However, pathologic response has rarely been precisely assessed on both primary tumor and its corresponding lymph nodes (LN) as an end-point. We performed this analysis on the CRC samples selected from the IMHOTEP trial, a multicenter, single-arm study evaluating peri-operative Pembrolizumab in 4 different cohorts of patients with localized resectable dMMR/MSI tumors. Methods: We analyzed pathologic response on the 56 surgical specimens available from the CRC cohort. Pathologic response was assessed on primary tumor according to the percentage of Residual Viable Tumor (RVT) score, encompassing 4 groups : 0% = pathologic Complete Response (pCR) ; ≤10% = Major Pathologic Response (MPR) ; >10% < 50% = partial Pathologic Response (pPR) ; > 50% = lack of response (noPR). Pathologic response was assessed on lymph node (LN) according to 4 groups : negative LN without sign of sterilization (yN0 reg-), negative LN with sterilization (yN0 reg+) ; metastatic LN without tumor regression (yN+ reg-) ; metastatic LN with tumor regression (yN+ reg+).The type of regression, including colloid, fibrotic and necrotic features was reported, as well as the presence of tertiary lymphoid structures (TLS). pCR and MPR corresponded to pathologic responder patients and pPR and noPR to pathologic non responder patients. Results: In thisCRC cohort pCR, MPR, pPR and noPR were observed in n= 33 (58.9%), 7 (12.5%), 5 (8.9%) and 11 (19.6 %) cases and yN0 reg-, yN0 reg+, yN+ reg-, yN+ reg+ in 41 (73.2%) , 7 (12.5%), 7 (12.5%), and 1 (1.8 % ) cases. There was a significant association between pathologic responders (pCR + MPR) and negative LN status encompassing sterilized LN (p=0.04). Pathologic responders were more frequently associated with classical (Lieberkuhnian) adenocarcinoma than with other CRC special subtypes (mucinous, signet ring-cell, poorly cohesive subtypes)(p<0.01). Colloid response was the most frequent pattern of regression, observed in 42 (75%) cases, and predominant (>80% of pathologic response areas) in 14 (25%) cases. TLS were seen in 46 (82%) cases, without any significant association with the RVT score. However TLS were observed in all CRC cases with MPR. Conclusions: These preliminary results show pembrolizumab efficacy as a neoadjuvant monotherapy in terms of pathologic response on both primary CRC and corresponding LN, highlighting the need for a new and more accurate pathologic score. It also illustrates the potential impact of the histological subtypes. Complementary data will be available after updated pathologic reviewing of additional specimens from CRC patients and will also be correlated with outcome. Clinical trial information: NCT04795661 .
Biopharma dealmaking in 2024
Exploring health related quality of life for women with breast cancer in Ireland and Québec, Canada throughout the COVID-19 pandemic
Abstract The long-term consequences from the COVID-19 pandemic on breast cancer (BC) is highly unknown, however persisting unmet needs and psychosocial difficulties are likely. The objectives of this study were to evaluate the change in health-related quality of life (HR-QoL) from the pandemic to post-pandemic for women living with a diagnosis of BC and to assess the association between COVID-19 stressor impact and HR-QoL in Ireland and Québec, Canada. Women with a diagnosis of BC were initially enrolled in the cohort study. HR-QoL was assessed during the pandemic (2020–2021) and post-pandemic periods (2022). COVID-19 stressor impact was computed post-pandemic, and change in HR-QoL during and post-pandemic was compared between Ireland and Québec using independent t-tests. Multivariable analysis of covariance (ANCOVA) was used to evaluate the association between COVID-19 stressor impact and changes in HR-QoL, and compare it between Ireland and Québec. 405 participants were included from both settings (Ireland n = 267; Québec n = 138). The average HR-QoL improved from the COVID-19 pandemic to post-pandemic, and there were no differences between Ireland and Québec. Women with high COVID-19 stressor impact (18.9% of participants) had a significantly smaller improvement in their overall HR-QoL compared to those with low COVID-19 stressor impact, and this was evident in Ireland (p < 0.004) and Québec (p < 0.0001) but there were no significant differences between Ireland and Québec (interaction p-value > 0.05). Overall, HR-QoL for women with BC improved from pandemic to post-pandemic period. However, similarly in both settings, women who experienced higher levels of COVID-19-related stress had a slower recovery in HR-QoL. These results can guide decisions about health services and policies to adequately address the on-going effect of the pandemic and also prepare for future health crises.